Purpose: To evaluate the use of positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) to assess early response to pre-operative chemoradiation therapy in combination with external locoregional hyperthermia in patients with oesophageal cancer by correlating the reduction of metabolic activity with histopathologic response.
Material And Methods: Twenty-six patients with histopathologically proven intra-thoracic oesophageal cancer (with < or =2 cm gastric involvement), scheduled to undergo a 5-week course of pre-operative chemoradiation therapy and hyperthermia, were included. FDG-PET was performed before (n = 26) and 2 weeks after initiation of therapy (n = 17). FDG uptake was quantitatively assessed by standardized uptake values.
Results: After neoadjuvant therapy, 24 of the 26 patients underwent surgery. In 16 patients changes in FDG uptake were correlated to histopathologic response. In these patients, histopathologic evaluation revealed less than 10% viable tumour cells in eight patients (responders) and more than 10% viable tumour cells in eight patients (non-responders). In responders, FDG uptake decreased by a median -44% (-75 to 2); in non-responders, it decreased by a median of -15% (-46 to 40). At a threshold of 31% decrease of FDG uptake compared with baseline, sensitivity to detect response was 75%, with a corresponding specificity of 75%. The positive and negative predictive values were both 75%.
Conclusion: FDG-PET is a promising tool for early response monitoring in patients undergoing chemoradiation therapy in combination with hyperthermia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/02656730500513523 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Developmental Venous Anomaly: Its Impact on Brain Parenchymal Function as Revealed by FDG PET.
Clin Nucl Med
January 2025
Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT.
Developmental venous anomaly (DVA) is a common benign brain vascular malformation, typically asymptomatic, with intervention required when complications arise. We present the case of a 63-year-old man with mild cognitive decline whose brain FDG PET showed decreased uptake not only at the site of DVA, but in the extended surrounding parenchyma where MRI showed no parenchymal abnormalities. DVAs arise from developmental irregularities in the embryonic venous system, but likely affecting a greater extent of the surrounding parenchymal functions.
View Article and Find Full Text PDFF-FAPI-42 PET/CT and F-FDG PET/CT in Patients with Malignant Digestive System Neoplasms: A Head-to-Head Comparative Study.
Mol Imaging Biol
January 2025
Department of Nuclear Medicine, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Purpose: Radionuclide-labeled fibroblast activation protein inhibitor (FAPI) is an emerging tumor tracer. We sought to assess the uptake and diagnostic performance of F-FAPI-42 PET/CT compared with simultaneous 2-deoxy-2[F]fluoro-D-glucose (F-FDG) PET/CT in primary and metastatic lesions in patients with malignant digestive system neoplasms and to determine the potential clinical benefit.
Procedures: Forty-two patients (men = 30, women = 12, mean age = 56.
Longitudinal FDG-PET Metabolic Change Along the Lewy Body Continuum.
JAMA Neurol
January 2025
Department of Radiology, Mayo Clinic, Rochester, Minnesota.
Importance: Although 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a well-established cross-sectional biomarker of brain metabolism in dementia with Lewy bodies (DLB), the longitudinal change in FDG-PET has not been characterized.
Objective: To investigate longitudinal FDG-PET in prodromal DLB and DLB, including a subsample with autopsy data, and report estimated sample sizes for a hypothetical clinical trial in DLB.
Design, Setting, And Participants: Longitudinal case-control study with mean (SD) follow-up of 3.
Exploring the Role of [Ga]Ga-DOTAGA-IAC and Comparison of Its Diagnostic Performance with [F]F-FDG PET/CT in Radioiodine Refractory Differentiated Thyroid Carcinoma.
Cancer Biother Radiopharm
January 2025
Advanced Innovative Partners, Inc. (AIP), Miami, Florida, USA.
Integrin antagonist complex (IAC), a novel αvβ3 integrin antagonist peptidomimetic, has emerged as a promising agent for molecular imaging of tumor angiogenesis. This study evaluates the biodistribution and clinical efficacy of [Ga]Ga-DOTAGA-IAC PET/CT in detecting radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), comparing its diagnostic performance with [F]F-FDG PET/CT. In this prospective pilot study, RAIR-DTC patients underwent whole-body imaging with [F] F-FDG PET/CT, followed by [Ga]Ga-DOTAGA-IAC PET/CT.
View Article and Find Full Text PDFWhole-body tumor segmentation from FDG-PET/CT: Leveraging a segmentation prior from tissue-wise projections.
Heliyon
January 2025
Radiology, Department of Surgical Sciences, Uppsala University, Uppsala, SE-75185, Sweden.
: Accurate tumor detection and quantification are important for optimized therapy planning and evaluation. Total tumor burden is also an appealing biomarker for clinical trials. Manual examination and annotation of oncologic PET/CT is labor-intensive and demands a high level of expertise.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!